Type 2 Diabetes

Despite being on first-line oral anti-diabetic drug therapy, the risk of developing CVD/CKD in patients with type 2 diabetes remains high.

The Look AHEAD trial had dramatic results for patients with T2D and their risk for cardiovascular disease (CVD). 

Black patients may have lower odds of achieving target HbA1C levels on metformin and SGLT2 alone. 

By Sheri Colberg, PhD
I recently was asked about the latest research on the reversal of type 2 diabetes—both bariatric and non-bariatric solutions—and it made me wonder about the mechanisms of this possibility and what role being active may play in it. Each new year always brings a whole host of resolutions that people make focused on losing weight, getting more fit, and becoming healthier. Especially with all the COVID-related pounds I have heard about people gaining, I expect these resolutions to be out in full force at the start of 2022. But how effective will they be long-term, and is the reversal of type 2 diabetes a realistic resolution to make?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors were created to treat diabetes, but noted to ameliorate cardiovascular events. 

Health plans with high deductibles require thousands of dollars out-of-pocket and have a known association with delays in treatment; a repeated cross-sectional study found they are also associated with medication non-adherence.

The case for why an SGLT2 inhibitor or GLP-1 receptor agonist should be initiated early in diabetes treatment, regardless of whether the patient is on insulin therapy.

Researchers showed that elevated blood pressure is a modifiable risk factor for new-onset type 2 diabetes.

The mean age at diagnosis of diabetes for non-Hispanic Black and Hispanic adults was 4-7 years earlier than for non-Hispanic white adults.

Many foods are marked with the whole-grain stamp of approval, but are these products equivalent in terms of glycemic control?